Bone Health and Osteoporosis

Bone

Discover Updates in New and Emerging Therapies

Sessions, journal articles, and point of care tools highlight the molecular discoveries and evolving treatment options for rare metabolic bone diseases and osteoporosis in patients of all ages.

Menopausal Hormone Therapy Improves Bone Health
November 17, 2016 | Study reveals bone density, structure benefits persist after treatment ends. Women who undergo hormone therapy for menopausal symptoms such as hot flashes can not only increase…

Customized Vitamin D Supplements May Benefit Pregnant Women
October 27, 2016 | Doses can be tailored to compensate for individual risk factors, protect bone health. Individualized supplement doses help protect pregnant women from vitamin D deficiency, according…

Chemical Exposure Linked to Lower Vitamin D Levels
September 20, 2016 | Endocrine-disrupting chemicals may alter active form of vitamin in body. Exposure to bisphenol A (BPA) and other endocrine-disrupting chemicals (EDCs) may reduce levels of vitamin D…

Case-Based Update on Hypoparathyroidism
CEU Satellite Symposium | 2.0 AMA PRA Category 1 Credits™
Chair: Steven T. Harris, MD
Faculty: Susan M. Ott, MD; Lynn A. Kohlmeier, MD; and Nelson B. Watts, MD
Weigh the traditional and contemporary treatment options with discussions on diagnostic and etiology.

Hypoparathyroidism @Point of Care
Practice Resource | No credit available
Find practical information when you need it the most to recognize signs, interpret results, and guide treatment decisions.

Hypophosphatasia: New Options in the Management of Alkaline Phosphatase Deficiency
ENDO Satellite Symposium | 2.0 AMA PRA Category 1 Credits™ and ABIM MOC Part 2 points
Chair: Jill H. Simmons, MD
Faculty: Nancy S. Dunbar, MD, MPH; Peter J. Tebben, MD; and Michael P. Whyte, MD
What does low alkaline phosphatase mean in practice? Recognize subtle signs of HPP in pediatric and adult patients and learn about the most recent treatment approvals.

New Frontiers in Osteoporosis: Targets in Bone Remodeling
ENDO Satellite Symposium | 2.0 AMA PRA Category 1 Credits™ and ABIM MOC Part 2 points
Chair: Michael R. McClung, MD
Faculty: Paul D. Miller, MD; Bente Lomholt Langdahl, PhD, DMSc; and Benjamin Zev Leder, MD
Keep up to date on the latest trials and emerging treatments in this rapidly evolving field.

Bone Health Digital Toolkit
Patient Resource | No credit available
Reviewer: Ramon E. Martinez, MD
Check out interactive and downloadable resources and information for patients with questions about maintaining bone health and disease.

Endocrine Facts & Figures: Bone and Mineral
Research Resource | No credit available
Advisory Panel Chair: Robert A. Vigersky, MD
Updated epidemiological data and in-depth discussion on disorders of bone and mineral metabolism with current citations and expert insights.

Determinants of the Maternal 25-Hydroxyvitamin D Response to Vitamin D Supplementation during Pregnancy
JCEM | October 28, 2016
Rebecca J. Moon, Nicholas C. Harvey, Cyrus Cooper, Stefania D'Angelo, Sarah R. Crozier, Hazel M. Inskip, Inez Schoenmakers, Ann Prentice, Nigel K. Arden, Nicholas J. Bishop, Andrew Carr, Elaine M. Dennison, Richard Eastell, Robert Fraser, Saurabh V. Gandhi, Keith M. Godfrey, Stephen Kennedy, M. Zulf Mughal, Aris T. Papageorghiou, David M. Reid, Sian M. Robinson, and M. Kassim Javaid
Context: Current approaches to antenatal vitamin D supplementation do not account for interindividual differences in 25-hydroxyvitamin D (25(OH)D) response. Objective: We assessed which maternal and…

Intraoperative Real-Time Localization of Normal Parathyroid Glands with Autofluorescence Imaging
JCEM | September 20, 2016
Sung Won Kim, Seo Hyun Song, Hyoung Shin Lee, Woong Jae Noh, Chulho Oak, Yeh-Chan Ahn, and Kang Dae Lee
Context: This biomedical investigation is valuable for identification and localization of parathyroid glands during thyroidectomy, which can provide an intraoperative real-time visual guidance. Objective: The…

Hormone Replacement Therapy versus the Combined Oral Contraceptive Pill in Premature Ovarian Failure: A Randomized Controlled Trial of the Effects on Bone Mineral Density
JCEM | June 24, 2016
Beth Cartwright, Jillian Robinson, Paul T. Seed, Ignac Fogelman and Janice Rymer
Context: Women with premature ovarian failure (POF) face many years of estrogen deficiency. One of the major consequences is bone loss. The optimal form of estrogen replacement…

Quantifying the Balance between Total Bone Formation and Total Bone Resorption: An Index of Net Bone Formation
JCEM | June 23, 2016
Albert Shieh, Weijuan Han, Shinya Ishii, Gail A. Greendale, Carolyn J. Crandall and Arun S. Karlamangla
Context: Bone gain vs loss across the skeleton loss depends on the balance between total bone formation and total bone resorption. Objective: The objective of the study…

Denosumab or Zoledronic Acid in Postmenopausal Women with Osteoporosis Previously Treated With Oral Bisphosphonates
JCEM | June 6, 2016
P. D. Miller, N. Pannacciulli, J. P. Brown, E. Czerwinski, B. S. Nedergaard, M. A. Bolognese, J. Malouf, H. G. Bone, J.-Y. Reginster, A. Singer, C. Wang, R. B. Wagman and S. R. Cummings
Context: Denosumab and zoledronic acid (ZOL) are parenteral treatments for patients with osteoporosis. Objective: The objective of the study was to compare the effect of transitioning…

Complex Genomic Rearrangement Within the GNAS Region Associated With Familial Pseudohypoparathyroidism Type 1b
JCEM | June 2, 2016
Akie Nakamura, Erika Hamaguchi, Reiko Horikawa, Yasuyuki Nishimura, Keiko Matsubara, Shinichiro Sano, Keisuke Nagasaki, Yoichi Matsubara, Akihiro Umezawa, Toshihiro Tajima, Tsutomu Ogata, Masayo Kagami, Kohji Okamura and Maki Fukami
Context: Pseudohypoparathyroidism type 1b (PHP-1b) results from methylation defects at the G protein stimulatory α subunit (GNAS) exon A/B-differentially methylated region (DMR). Although microduplications in…

Effects of High-Dose Vitamin D2 Versus D3 on Total and Free 25-Hydroxyvitamin D and Markers of Calcium Balance
JCEM | May 18, 2016
Albert Shieh, Rene F. Chun, Christina Ma, Sten Witzel, Briana Meyer, Brandon Rafison, Leon Swinkels, Tonnie Huijs, Sam Pepkowitz, Brett Holmquist, Martin Hewison and John S. Adams
Context: Controversy persists over: 1) how best to restore low serum 25-hydroxyvitamin D (25D) levels (vitamin D2 [D2] vs vitamin D3 [D3]); 2) how best…

Epidemiology and Health-Related Quality of Life in Hypoparathyroidism in Norway
JCEM | May 17, 2016
Marianne C. Astor, Kristian Løvås, Aleksandra Debowska, Erik F. Eriksen, Johan A. Evang, Christian Fossum, Kristian J. Fougner, Synnøve E. Holte, Kari Lima, Ragnar B. Moe, Anne Grethe Myhre, E. Helen Kemp, Bjørn G. Nedrebø, Johan Svartberg and Eystein S. Husebye
Objective: The epidemiology of hypoparathyroidism (HP) is largely unknown. We aimed to determine prevalence, etiologies, health related quality of life (HRQOL) and treatment pattern of HP…

Therapy of Hypoparathyroidism With PTH(1–84): A Prospective Six Year Investigation of Efficacy and Safety
JCEM | May 4, 2016
Mishaela R. Rubin, Natalie E. Cusano, Wen-Wei Fan, Yasmine Delgado, Chengchen Zhang, Aline G. Costa, Serge Cremers, Elzbieta Dworakowski and John P. Bilezikian
Context: Human recombinant (rh)PTH(1–84) was recently approved for the treatment of refractory hypoparathyroidism, based upon a short-term phase 3 clinical trial. Long-term data are needed…

Management of Hypoparathyroidism: Summary Statement and Guidelines
JCEM | March 4, 2016
Maria Luisa Brandi, John P. Bilezikian, Dolores Shoback, Roger Bouillon, Bart L. Clarke, Rajesh V. Thakker, Aliya A. Khan and John T. Potts Jr
Objective: Hypoparathyroidism is a rare disorder characterized by hypocalcemia and absent or deficient PTH. This report presents a summary of current information about epidemiology, presentation…

Bone and Mineral Metabolism: Where Are We, Where Are We Going, and How Will We Get There?
JCEM | February 23, 2016
Henry M. Kronenberg
Advances in diagnosing and treating metabolic bone diseases will require ways to assess cellular signaling within human bones, ideally noninvasively. Only then will we be…

Evaluation of Bone Mineral Density and Bone Biomarkers in Patients With Type 2 Diabetes Treated With Canagliflozin
JCEM | November 18, 2015
John P. Bilezikian, Nelson B. Watts, Keith Usiskin, David Polidori, Albert Fung, Daniel Sullivan and Norm Rosenthal
Context: Canagliflozin is a sodium glucose cotransporter 2 inhibitor developed to treat type 2 diabetes mellitus (T2DM). Objective: Our objective is to describe the effects of canagliflozin…

Asfotase Alfa Treatment Improves Survival for Perinatal and Infantile Hypophosphatasia
JCEM | November 3, 2015
Michael P. Whyte, Cheryl Rockman-Greenberg, Keiichi Ozono, Richard Riese, Scott Moseley, Agustin Melian, David D. Thompson, Nicholas Bishop and Christine Hofmann
Context: Hypophosphatasia (HPP) is an inborn error of metabolism that, in its most severe perinatal and infantile forms, results in 50–100% mortality, typically from…

Paget's Disease of Bone
JCEM | November 19, 2014
Frederick R. Singer, Henry G. Bone III, David J. Hosking, Kenneth W. Lyles, Mohammad Hassan Murad, Ian R. Reid, and Ethel S. Siris
We recommend that plain radiographs be obtained of the pertinent regions of the skeleton in patients with suspected Paget's disease. If the diagnosis is confirmed…

Osteoporosis in Men
JCEM | July 02, 2013
Nelson B. Watts, Robert A. Adler, John P. Bilezikian, Matthew T. Drake, Richard Eastell, Eric S. Orwoll, and Joel S. Finkelstein
Osteoporosis in men causes significant morbidity and mortality. We recommend testing higher risk men [aged ≥70 and men aged 50–69 who have risk factors…

Evaluation, Treatment, and Prevention of Vitamin D Deficiency
JCEM | June 06, 2011
Michael F. Holick, Neil C. Binkley, Heike A. Bischoff-Ferrari, Catherine M. Gordon, David A. Hanley, Robert P. Heaney, M. Hassan Murad, and Connie M. Weaver
Considering that vitamin D deficiency is very common in all age groups and that few foods contain vitamin D, the Task Force recommended supplementation at…

World Congress on Osteoporosis Osteoarthritis and Musculoskeletal Diseases 2017
Dates: March 23 - 26, 2017
Location: Florence, Italy
Sponsor: European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) and International Osteoporosis Foundation (IOF)

Endocrine Fellows Series: Osteoporosis and Metabolic Bone Diseases
Dates: August 2 - 3, 2017
Location: Santa Fe, New Mexico, United States
Sponsor: Endocrine Society

American Society for Bone and Mineral Research 2017 Annual Meeting
Dates: September 8 - 11, 2017
Location: Colorado Convention Center, Denver, Colorado, United States
Sponsor: American Society for Bone and Mineral Research

Popular Resources